Fig. 4

Suppression of E2F3 inhibits tumor progression in vitro and in vivo. a and b Real-time PCR (a) and western blot (b) showed higher expression levels of E2F3 in tumor cell lines compared with normal cell lines. c E2F3 knockdown by two independent shRNAs. EGFP was used to track the shRNA vectors (Mock, shE2F3–1, shE2F3–2) in Y79, WERI-Rb-1 and 5637 cell lines. d and e A soft agar colony assay was performed to assess tumor formation ability of E2F3-silenced tumor cell lines (Y79, WERI-Rb-1 and 5637). f CCK8 assay was performed to assess cell proliferation of E2F3-silenced tumor cell lines (Y79, WERI-Rb-1 and 5637). g-h General photograph (g) and the weight (h) of orthotopic xenograft at the 35th day after injection of WERI-Rb-1 into the subretinal space with or without E2F3 knockdown; n = 8. The results were shown as Mean ± SD, **p < 0.01